Oxford candidate enters latestage clinical trials
2020-09-04 00:00
Latestage clinical trials for the socalled Oxford vaccine have begun in the United States, and developers say the first results determining the efficacy of this promising COVID inoculation candidate can be expected this year.Oxford University and development partner AstraZeneca, which is a pharmaceutical company based in Cambridge, England, confirmed that the first of , volunteers received doses in the US this week. The study is doubleblind, so volunteers and healthcare professionals will not know if an injection contains a placebo or AZD, which is commonly referred to as the Oxford vaccine and that was formerly known as ChAdOx nCoV.The USbased study joins three other Phase III trials taking place for this vaccine in the United Kingdom, Brazil, and South Africa.                                                                                                                                                                                                                                                                           !CDATA            function shareweixin              var ua  navigator.userAgent.toLowerCase              ifiphoneipadipod.testua  ua.matchMicroMessengeri  micromessenger                window.opena.app.qq.comosimple.jsp?pkgnamecom.theotino.chinadailyiosschemeencodeIos                            else ifandroid.testua  ua.matchMicroMessengeri  micromessenger                window.opena.app.qq.comosimple.jsp?pkgnamecom.theotino.chinadailyandroidschemeencodeAndroid                            else                window.openwww.chinadaily.com.cnmobiledaily.html